HLB Pharmaceutical Discloses KRW 120 Billion Rights Offering Plan

HLB Pharmaceutical disclosed on May 13, 2026 that it will conduct a paid-in capital increase worth KRW 120,000,001,800. The planned method is a shareholder allocation followed by a public offering of forfeited shares, meaning existing shareholders receive priority and any unsubscribed shares are then offered to general investors. The announcement represents a financing plan disclosed by the KOSDAQ-listed company. The new shares are stated as common shares, but the summarized source only partially confirms the detailed number. Investors should check later filings for the final issue price and subscription schedule. Source: mk.co.kr